This is, in particular, supported by a post mortem study revealing sparse Aβ plaques with advanced neurofibrillary tangle pathology (Braak stage V) in an aducanumab‐treated patient who progressed from moderate to end‐stage dementia, suggesting limited effects of Aβ clearance at advanced tau and clinical stages.19 The gene discussed is MAPT; the disease is dementia.